Deutsche Bank Increases GlaxoSmithKline plc Price Target to GBX 1,660 (GSK)
Investment analysts at Deutsche Bank lifted their target price on shares of GlaxoSmithKline plc (LON:GSK) from GBX 1,630 ($27.76) to GBX 1,660 ($28.27) in a note issued to investors on Wednesday. The firm currently has a “hold” rating on the stock. Deutsche Bank’s price objective indicates a potential upside of 5.83% from the company’s current price.
A number of other firms have also recently commented on GSK. Analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. They now have a GBX 2,100 ($35.77) price target on the stock. Separately, analysts at Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, June 20th. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Thursday, June 19th. They now have a GBX 1,610 ($27.42) price target on the stock. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 1,726.48 ($29.41).
GlaxoSmithKline plc (LON:GSK) traded down 0.35% on Wednesday, hitting GBX 1568.50. The stock had a trading volume of 4,420,247 shares. GlaxoSmithKline plc has a one year low of GBX 1200.668 and a one year high of GBX 1762.0001. The stock has a 50-day moving average of GBX 1600. and a 200-day moving average of GBX 1614.. The company’s market cap is £75.508 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.